Drug Trial Radar · NCT06975618
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
141
Planned (sponsor's estimate)
Start
Aug 22, 2023
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Haihe Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open-label, single arm, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33 in patients with PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (PRVM)
Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)
- PIK3CA-related Vascular Malformations (PRVM)
Interventions
CYH33Drug
CYH33: Participants will receive oral CYH33 once daily. The starting dose for adults in Phase I is 10 mg QD; adolescents begin at 5 mg QD. In Phase II, patients will receive RP2D determined in the Phase I study.
PlaceboDrug
Placebo: Matching placebo tablets will be administered once daily during the double-blind period of the Phase II PRVM cohort. Patients randomized to placebo will switch to CYH33 at the end of the blinded phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: The maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D)Time frame: 27 weeks
- Phase II PROS Cohort: BIRC-assessed objective response rate (ORR) at Week 24Time frame: Baseline to 24weeks
- Phase II PRVM Cohort: BIRC-assessed objective response rate (ORR) at Week 24Time frame: Baseline to 24weeks
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Capital Center for Children's Health, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Plastic Surgery Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China · Not yet recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Shanghai Ninth People Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Gifu University Hospital
Gifu, Japan · Recruiting
Tonan Hospital
Sapporo, Hokkaido, Japan · Recruiting
National Hospital Organization Kobe Medical Center
Kobe, Hyōgo, Japan · Recruiting
Yokohama City University Hospital
Yokohama, Kanagawa, Japan · Recruiting
Tohoku University Hospital
Sendai, Miyagi, Japan · Recruiting
Shinshu University Hospital
Matsumoto, Nagano, Japan · Recruiting
Kyorin University Hospital
Mitaka, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.